Dopamine receptors, in particular, the dopamine D2 receptor (D2R) constitute important drug targets for treatment of neuropsychiatric, neurological, and neuroendocrine disorders, such as Parkinson’s disease, schizophrenia, and hyperprolactinemia (Beaulieu and Gainetdinov 2011). This evidence concerns the gene DRD2 and schizophrenia.